Harrow Extends VEVYE® Access for All Program to Klarity-C Patients of ImprimisRx

Harrow Expands Access to VEVYE® for Klarity-C Patients at $59 Per Bottle Harrow (Nasdaq: HROW), a leading eyecare pharmaceutical company in North America, has announced the expansion of its VEVYE® Access for All (VAFA) program to include current users of…